Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase

MeSH terms

• Antineoplastic Agents / therapeutic use
• Benzamides / therapeutic use*
• Blast Crisis / complications
• Blast Crisis / genetics*
• Blast Crisis / mortality
• Eosinophilia / drug therapy
• Eosinophilia / etiology*
• Eosinophilia / mortality
• Follow-Up Studies
• Gene Rearrangement
• Humans
• Imatinib Mesylate
• Leukemia, Myeloid / complications
• Leukemia, Myeloid / drug therapy
• Leukemia, Myeloid / genetics*
• Leukemia, Myeloid / mortality
• Lymphoma, T-Cell / complications
• Lymphoma, T-Cell / drug therapy
• Lymphoma, T-Cell / genetics*
• Lymphoma, T-Cell / mortality
• Oncogene Proteins, Fusion / genetics
• Piperazines / therapeutic use*
• Prognosis
• Pyrimidines / therapeutic use*
• Receptor, Platelet-Derived Growth Factor alpha / genetics
• Receptor, Platelet-Derived Growth Factor beta / genetics*
• Sarcoma, Myeloid / complications
• Sarcoma, Myeloid / drug therapy
• Sarcoma, Myeloid / genetics*
• Sarcoma, Myeloid / mortality
• Survival Rate
• mRNA Cleavage and Polyadenylation Factors / genetics